Top

International Journal of Clinical Oncology

Published in:

29-03-2024 | Myelodysplastic Syndrome | PMDA Regulatory Update

PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan

Authors: Noriomi Matsumura, Masaki Mandai

Published in: International Journal of Clinical Oncology | Issue 5/2024

Excerpt

Approval of New Drugs Pharmaceuticals and Medical Devices Agency (PMDA) in Japan approved the following drugs in January 2024. …

Pharmaceuticals and Medical Devices Agency (2024) Review report for talazoparib tosilate (in Japanese). https://www.pmda.go.jp/drugs/2024/P20240205001/672212000_30600AMX00015_A100_1.pdf. Accessed 5 Mar 2024

Schreiber V, Dantzer F, Ame JC et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517–528. https://doi.org/10.1038/nrm1963CrossRefPubMed

Pommier Y, O’Connor MJ, de Bono J (2016) Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 8:36217. https://doi.org/10.1126/scitranslmed.aaf9246CrossRef

Murai J, Huang SN, Das BB et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753CrossRefPubMedPubMedCentral

Lord J, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287–294. https://doi.org/10.1038/nature10760CrossRefPubMed

Pharmaceuticals and Medical Devices Agency (2024) Review report for luspatercept (in Japanese). https://www.pmda.go.jp/drugs/2024/P20240112001/670605000_30600AMX00021_A100_1.pdf. Accessed 5 Mar 2024

Zeidan AM, Linhares Y, Gore SD (2013) Current therapy of myelodysplastic syndromes. Blood Rev 27:243–259. https://doi.org/10.1016/j.blre.2013.07.003CrossRefPubMedPubMedCentral

Title: PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Authors: Noriomi Matsumura
Masaki Mandai
Publication date: 29-03-2024
Publisher: Springer Nature Singapore
Keywords: Myelodysplastic Syndrome
Breast Cancer
Breast Cancer
Published in: International Journal of Clinical Oncology / Issue 5/2024
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02510-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2024

Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay

Lymphatic drainage patterns of malignant skin tumors in the head and neck region: a single-center retrospective study

Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer